Livzon Pharmaceutical Group Inc. (SHE:000513)

Market Cap	25.46B -8.1%
Revenue (ttm)	11.71B -0.3%
Net Income	1.96B -6.1%
EPS	2.20 -3.9%
Shares Out	887.91M
PE Ratio	14.15
Forward PE	13.07
Dividend	1.10 (3.53%)
Ex-Dividend Date	Jun 13, 2025

Volume	1,685,700
Average Volume	5,595,983
Open	30.90
Previous Close	31.18
Day's Range	30.90 - 31.25
52-Week Range	30.54 - 44.87
Beta	0.28
RSI	31.51
Earnings Date	Apr 23, 2026

About SHE:000513

Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 8,878
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000513

Financial Performance

In 2025, SHE:000513's revenue was 12.02 billion, an increase of 1.76% compared to the previous year's 11.81 billion. Earnings were 2.02 billion, a decrease of -1.84%.